Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 33: 1211-1212, 1987;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flick, J. A.
Right arrow Articles by Perman, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flick, J. A.
Right arrow Articles by Perman, J. A.

Clinical Chemistry, Vol 33, 1211-1212, Copyright © 1987 by American Association for Clinical Chemistry

Thin-layer chromatographic determination of urinary excretion of lactulose, simplified and applied to cystic fibrosis patients

JA Flick, RL Schnaar and JA Perman

Urinary excretion of orally administered lactulose is used as an index of intestinal permeability. We have developed a simple thin-layer chromatographic technique for measuring lactulose in urine, using silica gel 60 plates and a propanol-borate solvent system. Lactulose concentrations as low as 62.5 mg/L can be detected with high reproducibility and without interference by urinary chromogens. After oral administration, the urinary excretion of lactulose in 8 h equaled 2.33 (SD 1.86)% in 15 patients with cystic fibrosis, as compared with 0.13 (SD 0.12)% in 16 healthy subjects (P less than 0.001).




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the American Association for Clinical Chemistry.